Arvinas, Inc. (ARVN) has a MoatMap StockRank of 14/100 based on Quality (35/100), Value (41/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL. Arvinas is a clinical-stage biotechnology company developing targeted protein degraders. While its PROTAC platform is scientifically innovative, the company is pre-revenue, highly capital-consumptive, and lacks the established cash flows, high ROIC, and pricing power required by our Terry Smith and Warren Buffett lenses. It does not align with our CDMO theme as it is a drug developer rather than a scaled manufacturer.
Arvinas, Inc. is a clinical-stage biopharmaceutical company pioneering the development of novel therapies through its proprietary PROTAC® protein degradation technology. The company holds a leading position in this innovative therapeutic modality, which aims to selectively degrade disease-causing proteins, opening new avenues for treating intractable diseases. Its advanced platform and strategic collaborations with major pharmaceutical companies underpin its competitive advantage in a high-potential, disruptive biotechnology space.
| Price | $7.21 |
| Market Cap | $570M |
| P/E (Forward) | -2.32 |
| Price/Book | 1.29 |
| Return on Equity | -42.3% |
| Return on Invested Capital | -20.6% |
| Debt/Equity | 2.17 |
| Gross Margin | 134.5% |
| Operating Margin | -405.1% |
| Revenue Growth | -91.7% |
| Free Cash Flow | $-200M |
Arvinas, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).